Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24959140 | 1.00 | FFAR1 (0.52) | FFAR1DGAT1IRAK4LPLLIPG | |
| SCHEMBL253540 | 0.92 | FFAR1 (0.57) | FFAR1DGAT1IRAK4LPLLIPG | |
| SCHEMBL1986801 | 0.89 | FFAR1 (0.52) | FFAR1DGAT1IRAK4LPLLIPG | |
| SCHEMBL21456459 | 0.89 | FFAR1 (0.52) | FFAR1IRAK4LPLLIPG | |
| SCHEMBL2746946 | 0.88 | FFAR1 (0.53) | FFAR1DGAT1IRAK4LPLLIPG | |
| SCHEMBL27031982 | 0.86 | FFAR1 (0.56) | FFAR1DGAT1IRAK4LPLLIPG | |
| SCHEMBL1855038 | 0.86 | FFAR1 (0.55) | FFAR1DGAT1IRAK4LPLLIPG | |
| SCHEMBL3004343 | 0.86 | FFAR1 (0.55) | FFAR1DGAT1IRAK4LPLLIPG | |
| SCHEMBL16898368 | 0.83 | FFAR1 (0.46) | FFAR1 | |
| SCHEMBL16898441 | 0.83 | FFAR1 (0.46) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166109-B | Aminopyridine compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20220017483-A1 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN-KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD (CN) | 2022-01-20 | — | — | US | disclosed |
| CN-113166109-A | Aminopyridine compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020135195-A1 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-07-02 | — | — | WO | disclosed |
| US-8822468-B2 | 3-Methyl-imidazo[1,2-b]pyridazine derivatives | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2265614-A1 | IMIDAZO [1,2-B]PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | Novartis AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | NOVARTIS AG | 2009-10-22 | — | — | US | disclosed |
| WO-2009106577-A1 | IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264406-A1 | 3-METHYL-IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | MET, ERBB2, ALK | FFAR1 1712/4885DGAT1 4879/4885IRAK4 124/4885 |
| US-20220017483-A1 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | ADORA1, ADORA2A, ADORA2B | FFAR1 46/4885DGAT1 4089/4885IRAK4 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.